Rosnilimab demonstrated the highest ever reported CDAI low disease activity (LDA) response at Week 14, with 69% of patients achieving LDA. How does this compare to current RA treatment options, and what are the clinical implications of such a high response rate?

Unlike traditional RA treatments that primarily target cytokines or B cells, Rosnilimab depletes PD-1high T cells while agonizing remaining PD-1+ T cells. Can you explain the significance of this mechanism and how it might alter long-term disease progression in RA patients?

The data suggest that Rosnilimab-treated patients show sustained CDAI LDA and ACR50 responses, with potentially deepening ACR70 responses out to Week 28. What does this suggest about the potential for Rosnilimab to provide long-term disease modification rather than just symptom control?

RA treatment options include TNF inhibitors, JAK inhibitors, and IL-6 inhibitors, among others. How does Rosnilimab compare to these existing therapies in terms of efficacy, safety, and potential patient population suitability?

Rosnilimab was well tolerated, with adverse event rates comparable to placebo, no malignancies, and no serious infections reported. How important is this safety profile for RA patients, particularly those who may have experienced side effects with other immunosuppressive treatments?

With additional data expected from the Phase 2 trial in ulcerative colitis later this year, how might Rosnilimab’s mechanism of action be applicable to other autoimmune or inflammatory diseases beyond RA?

Given the promising Phase 2b data, what are the key considerations for Rosnilimab’s advancement into Phase 3 trials? Are there specific endpoints or patient subgroups that will be critical for regulatory approval and market positioning?

Rosnilimab’s approach represents a shift in RA treatment by leveraging immune system modulation rather than broad immunosuppression. Do you see PD-1+ T cell targeting as a potential new treatment paradigm in autoimmune diseases, and how might this influence future drug development?